Sight Sciences Announces the Results of the Three-Year Prospective GEMINI Trial and the Cross-Over Phase of the SAHARA RCT at the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
April 02, 2024 16:05 ET
|
Sight Sciences, Inc.
Clinical results demonstrate long-term efficacy of the OMNI® Surgical System for primary open-angle glaucoma and support use of TearCare® technology as a primary treatment for dry eye disease. ...
Sight Sciences to Present at the Upcoming 23rd Annual Needham Healthcare Conference
March 26, 2024 16:05 ET
|
Sight Sciences, Inc.
MENLO PARK, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and...
Sight Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Initiates Full Year 2024 Financial Guidance
March 07, 2024 16:05 ET
|
Sight Sciences, Inc.
MENLO PARK, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and...
Sight Sciences to Report Fourth Quarter and Full Year 2023 Financial Results on March 7, 2024
February 22, 2024 16:05 ET
|
Sight Sciences, Inc.
MENLO PARK, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing...
Sight Sciences Announces European Launch of the Ergo-Series of the OMNI® Surgical System at the ESCRS Winter Meeting
February 14, 2024 16:05 ET
|
Sight Sciences, Inc.
MENLO PARK, Calif., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing...
Sight Sciences Announces the Closing of up to $65 Million Senior Secured Credit Facility with Hercules Capital
January 23, 2024 16:05 ET
|
Sight Sciences, Inc.
MENLO PARK, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences”), an eyecare technology company focused on developing and commercializing innovative...
Sight Sciences Announces Preliminary, Unaudited Fourth Quarter and Full Year 2023 Financial Highlights
January 08, 2024 16:05 ET
|
Sight Sciences, Inc.
MENLO PARK, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing...
Sight Sciences Announces Withdrawal of Final LCDs on Micro-Invasive Glaucoma Surgery from Five Medicare Administrative Contractors
December 28, 2023 09:15 ET
|
Sight Sciences, Inc.
MENLO PARK, Calif., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences”), an eyecare technology company focused on developing and commercializing innovative...
Sight Sciences Announces the Publication of Successful Results of the SAHARA Randomized Controlled Clinical Trial Comparing TearCare® to Restasis® for the Treatment of Dry Eye Disease
December 18, 2023 16:05 ET
|
Sight Sciences, Inc.
MENLO PARK, Calif., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and...
Sight Sciences Announces the Acceptance for Publication of GEMINI 2, a Three Year, Prospective, Multicenter Trial Demonstrating Sustained, Significant IOP and Medication Reductions Enabled with the OMNI® Surgical System Technology
December 08, 2023 08:05 ET
|
Sight Sciences, Inc.
Prospective, long-term trial results are consistent with the significant body of published clinical evidence demonstrating the durable safety and effectiveness of procedures enabled with the OMNI...